Patient Adherence, Communication and Engagement (PACE) - Increased Investment and Adoption of New Digital Tools Enable Key Stakeholder Collaborations and Encourage Compliance

• Publication date: November 2012
• Report size: 66 pages

Patient Adherence, Communication and Engagement (PACE) - Increased Investment and Adoption of New Digital Tools Enable Key Stakeholder Collaborations and Encourage Compliance Summary GBI Research, a leading business intelligence provider, has released its latest research, “Patient Adherence, Communication and Engagement (PACE) - Increased Investment and Adoption of New Digital Tools Enable Key Stakeholder C...

Patient Adherence, Communication and Engagement (PACE) - Increased Investment and Adoption of New Digital Tools Enable Key Stakeholder Collaborations and Encourage Compliance



Summary



GBI Research, a leading business intelligence provider, has released its latest research, “Patient Adherence, Communication and Engagement (PACE) - Increased Investment and Adoption of New Digital Tools Enable Key Stakeholder Collaborations and Encourage Compliance”. The report focuses on the US health system’s efforts to improve patient engagement and medication adherence. Key topics of the report include reforms in the US healthcare industry, technology adoption, mobile and social media in healthcare, industry collaborations and examples of patient engagement and adherence interventions. There is a increasing focus on medication non-adherence as a critical challenge in the US healthcare system. When patients do not adhere to their prescribed medication or treatment regimen, it leads to reduced efficiency of treatment and increased utilization of care facilities. Healthcare expenditure is rising at an exponential rate, forcing the industry to focus on efficiencies in care delivery to control costs and improve health outcomes. Health insurance reforms and new payment and reimbursement models place emphasis on outcome-based performance measures. Rising healthcare costs have provided impetus to the health organizations to collaborate on their patient engagement interventions in an effort to control the epidemic of non-adherence. Federal stimulus has increased adoption of healthcare information technology by the providers, and payers are also increasingly adopting healthcare technology. The integration of information systems across care facilities gives greater access to data and enables collaboration between different players in the industry. Health industry players leverage these systems and use this increased access to data, in combination with other technologies, to improve their patient engagement efforts.



Scope


- Key drivers in the healthcare landscape increasing health organizations’ focus and efforts on adherence
- Implications for industry stakeholders, pharmaceutical manufacturers, health plans and healthcare providers
- Examples of collaborative efforts within key stakeholder groups
- Analysis of the key technology trends within the healthcare industry
- Examples of adherence interventions that leverage technology to achieve their goals



Reasons to buy


- Understand how the changing healthcare landscape is influencing different stakeholder groups to focus on patient engagement
- Understand how industry players are forging collaborations with other organizations in their adherence efforts
- Explore the effectiveness of social media and mobile campaigns
- Analyze existing healthcare technologies that support patient engagement efforts
- Analyze existing engagement best practices in adherence efforts
- Develop effective adherence interventions that leverage technology for patient outreach

Therapy Industry in the United States

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 6
1.2 List of Figures 7
2 Patient Adherence, Communication and Engagement (PACE) - Introduction 8
3 Patient Adherence, Communication and Engagement (PACE) - Market Dynamics 9
3.1 Medication Non-adherence Gains Industry-wide Attention 9
3.2 Key Trends in Healthcare Landscape Driving Investment in Adherence Programs 10
3.2.1 Change Drivers in the Healthcare Industry 10
3.2.2 Opportunities and Challenges in the New Healthcare Landscape 11
3.2.3 Healthcare Reform - Increasing Access and Improving Outcomes 12
3.2.4 Changing Priorities in Healthcare Landscape 14
3.2.5 HITECH - Outlined Criteria for Meaningful Use of EHRs 19
3.2.6 HHS Health Data Initiative - Accessible Data is Seen as a Change Driver in Healthcare 19
3.3 Implications for Pharmaceutical Industry 20
3.4 Trends Showing the Way Forward 21
3.4.1 Healthcare Technology Trends 21
3.4.2 Medication Therapy Management 23
3.4.3 Shifting Gears - mHealth Leveraging Smart Phones and Personal Devices 26
3.4.4 Rising Prominence of Social Media and Online Networking 28
3.4.5 Healthcare Collaboration across Continuum of Care 30
4 Patient Adherence, Communication and Engagement (PACE) - Role of Collaborations 31
4.1 Key Stakeholders in Patient Adherence and Engagement Initiatives 31
4.1.1 Patient Engagement Efforts of Pharmaceutical Industry 31
4.1.2 Healthcare Providers 32
4.1.3 Health Plans 32
4.2 Examples of Successful Industry Collaborations 33
4.2.1 Employer Diabetes Program in Collaboration with Healthcare Providers and Drug Maker Achieves Patient Engagement 33
4.2.2 Community-wide Preventive and Disease Management Initiative by Multiple Stakeholder Alliance 34
4.2.3 Manufacturers Collaborate with Payers to Use Claims Data for New Drug Discovery 36
4.2.4 Integrated Social Media Campaign in Partnership with Patient Groups 36
5 Patient Adherence, Communication and Engagement (PACE) - Technology as Enabler 38
5.1 Healthcare IT in Promoting Adherence 38
5.1.1 EHR and Health Data in Monitoring and Tailoring Adherence Programs 38
5.1.2 PHR as a Tool to Engage Patients in Self-management 39
5.1.3 Technology Integration - Personal and Home Health Devices 40
5.1.4 Engaging Physicians and Patients with mHealth 40
5.1.5 Social Media Campaigns by Health Organizations and Pharmaceuticals 41
5.2 Case Studies - Technology Solutions Utilized in Engagement and Adherence Initiatives 43
5.2.1 Leveraging Existing Data from EHR for Driving Adherence Interventions 43
5.2.2 Engaging with the Diabetes Community through Social Media 47
5.2.3 Personal Devices to Promote Patient Engagement in Healthcare 50
5.2.4 Utilizing a Combination of Technologies for Engaging Patients in Self-management 53
5.2.5 Integrating Data Captured by Home Health Devices with EMR 55
6 Patient Adherence, Communication and Engagement (PACE) - Conclusions 57
6.1 Collaboration is Critical for Success in Adherence Initiatives 57
6.2 Technology as an Enabler for Improving Adherence 57
7 Patient Adherence, Communication and Engagement (PACE) - Appendix 59
7.1 Market Definition 59
7.2 Abbreviations 59
7.3 References 60
7.4 Research Methodology 65
7.4.1 Coverage 65
7.4.2 Secondary Research 65
7.4.3 Primary Research 65
7.4.4 Expert Panel Validation 66
7.5 Contact Us 66
7.6 Disclaimer 66

1.1 List of Tables

Table 1: PACE Industry Drivers, Challenges and Opportunities, 2012 11
Table 2: PACE, % of Medicare FFS Beneficiaries, The US, by Number of Chronic Conditions and Age, 2008 15
Table 3: PACE, Distribution of Medicare FFS Beneficiaries, The US, by Number of Chronic Conditions and Healthcare Utilization, 2008 16
Table 4: PACE, Mean Expenses per Person with Healthcare Expenses, The US, by Service Type, ($) 2009 17
Table 5: PACE, Active Prescribers Using EHRs vs. Standalone E-prescribing Systems, The US, (%), 2008-2011 22
Table 6: PACE, Written Summaries Provided to Beneficiaries, The US, by % of MTM Programs, 2010-2011 24
Table 7: PACE, Beneficiary Interventions, The US, % of MTM Programs, 2010-2011 25
Table 8: PACE, Provider of MTM Services, The US, by % of MTM Programs, 2010-2011 26
Table 9: PACE, Subscriber Base per 100 Inhabitants, The US, by ICT Type, 2006-2011 27
Table 10: PACE, Social Media Presence, the US, by Hospital, 2012 28
Table 11: PACE, Diabetes Prevention Program, Program Outcomes, 2012 35
Table 12: PACE, Adult Asthma Prevalence, Michigan, by Age, 2008 44
Table 13: PACE, Michigan, Child Asthma Prevalence, by Age, 2008 44
Table 14: PACE, Diabetes Therapeutics Market, The US, Revenue ($bn), 2003-2010 47
Table 15: PACE, Diabetes Therapeutics Market, The US, Revenue Forecasts ($bn), 2010-2017 48
Table 16: PACE, Multi-channel Diabetes Campaign, Social Media Components, 2009-2012 48
Table 17: PACE, Multi-channel Diabetes Campaign, Social Media Performance, 2009-2012 49
Table 18: PACE, Adults with Diagnosed Diabetes, Georgia, % by Age, 2001-2010 51
Table 19: PACE, Diabetes Treatment Program, Technologies, 2008 53
Table 20: PACE, Hypertension Control Intervention, Technologies, 2012 54
Table 21: PACE, Hypertension Control Initiative, Technologies, 2012 56

1.2 List of Figures

Figure 1: PACE Industry Drivers, 2012 10
Figure 2: PACE, % of Medicare FFS Beneficiaries, The US, by Number of Chronic Conditions and Age, 2008 14
Figure 3: PACE, Distribution of Medicare FFS Beneficiaries, The US, by Number of Chronic Conditions and Healthcare Utilization, 2008 15
Figure 4: PACE, Mean Expenses per Person with Healthcare Expenses, The US, by Service Type, ($), 2009 17
Figure 5: PACE, National Health Spending, The US, by Sponsors, ($tn), 2010 18
Figure 6: PACE, Active Prescribers Using EHRs vs. Standalone E-prescribing Systems, The US, (%), 2008-2011 22
Figure 7: PACE, Written Summaries Provided to Beneficiaries, The US, by % of MTM Programs, 2010-2011 23
Figure 8: PACE, Beneficiary Interventions, The US, % of MTM Programs, 2010-2011 24
Figure 9: PACE, Provider of MTM Services, The US, by % of MTM Programs, 2010-2011 25
Figure 10: PACE, Subscriber Base per 100 Inhabitants, the US, by ICT Type, 2006-2011 26
Figure 11: PACE, FDA Guidelines on Responding to Unsolicited Information on Social Media, the US, 2011 29
Figure 12: PACE, Diabetes Care Program, Program Outcomes, 2007–2009 34
Figure 13: PACE, Pain Awareness Raising Initiative in Partnership with Patient Groups, Global, 2010 37
Figure 14: PACE, Adult Asthma Prevalence, Michigan, by Age, 2008 43
Figure 15: PACE, Child Asthma Prevalence, Michigan, by Age, 2008 44
Figure 16: PACE, Asthma Wellness Program, Program Outcomes, 2012 46
Figure 17: PACE, Diabetes Therapeutics Market, The US, Revenue Forecasts ($bn), 2003-2017 47
Figure 18: PACE, Adults With Diagnosed Diabetes, Georgia, % by Age, 2001-2010 51
Figure 19: PACE, Diabetes Treatment Program, Program Outcomes, 2008 52
Figure 20: PACE, Hypertension Control Initiative, Program Outcomes, 2012 56